ASX:CUV Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Clinuvel Pharmaceuticals Stock (ASX:CUV) 30 days 90 days 365 days Advanced Chart Ad Investors AlleyThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.Click here to get the full story >> Get CUV alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume124,193 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield0.36%Price TargetN/AConsensus RatingN/A Company OverviewClinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.Read More… The #1 ETF for monthly income (Ad)We just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.Click here to get the full story >> Receive CUV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CUV Stock News HeadlinesClinuvel Pursues Expanded SCENESSE® Dosage in EuropeNovember 20 at 9:52 AM | markets.businessinsider.comClinuvel Pharmaceuticals Tackles Market Challenges and OpportunitiesNovember 18, 2024 | markets.businessinsider.comThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.November 22, 2024 | Investors Alley (Ad)Clinuvel Pharmaceuticals Refocuses on Core Programs for GrowthNovember 18, 2024 | markets.businessinsider.comMA Financial Group Sticks to Its Buy Rating for Clinuvel Pharmaceuticals Limited (CLVLF)October 30, 2024 | markets.businessinsider.comHealth Check: 4D Medical investors – and burns pit victims – can breathe easier after US lung-imaging dealOctober 1, 2024 | msn.comTop Growth Companies With Significant Insider OwnershipSeptember 28, 2024 | finance.yahoo.comSeptember 2024's Top Growth Picks With High Insider OwnershipSeptember 20, 2024 | finance.yahoo.comSee More Headlines CUV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Clinuvel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clinuvel Pharmaceuticals investors own include Cochlear (COH), CSL (CSL), ResMed (RMD), ARB (ARB), Accent Group (AX1), Corporate Travel Management (CTD) and Mineral Resources (MIN). Company Calendar Ex-Dividend for 9/19 Dividend9/04/2024Dividend Payable9/19/2024Today11/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CUV CUSIPN/A CIKN/A Webwww.clinuvel.com Phone61 3 9660 4900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.70 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$35.64 million Net Margins40.41% Pretax MarginN/A Return on Equity19.39% Return on Assets14.29% Debt Debt-to-Equity Ratio0.43 Current Ratio8.81 Quick Ratio10.03 Sales & Book Value Annual Sales$88.18 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow19.36 Book ValueA$4.05 per share Price / BookN/AMiscellaneous Outstanding Shares50,060,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.92 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (ASX:CUV) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe #1 Bitcoin ETF For Monthly DividendsYou don't have to own any Bitcoin to collect BIG dividends from it... Now, thanks to this brand new Bitcoin...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinuvel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
